Real-World Treatment Patterns and Outcomes Across Three Lines of Therapy in Patients with ALK+ NSCLC
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Real-World Treatment Patterns and Outcomes Across Three Lines of Therapy in Patients with ALK+ NSCLC ; volume:41 ; number:8 ; day:25 ; month:6 ; year:2024 ; pages:3217-3231 ; date:8.2024
Advances in therapy ; 41, Heft 8 (25.6.2024), 3217-3231, 8.2024
- Urheber
-
Arnaoutakis, Konstantinos
Wan, Yin
Elliott, Jennifer
Young, Matt
Yin, Yu
Leventakos, Konstantinos
Lin, Huamao M.
Dimou, Anastasios
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s12325-024-02899-6
- URN
-
urn:nbn:de:101:1-2410072110052.342860858875
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:29 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Arnaoutakis, Konstantinos
- Wan, Yin
- Elliott, Jennifer
- Young, Matt
- Yin, Yu
- Leventakos, Konstantinos
- Lin, Huamao M.
- Dimou, Anastasios
- SpringerLink (Online service)
Ähnliche Objekte (12)
Alecensa bei ALK-positivem NSCLC
Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
Inhibiting ALK-TOPK signaling pathway promotes cell apoptosis of ALK-positive NSCLC
Therapie des ALK+ NSCLC - Brigantinib in der Erstlinie [1, 3] : nicht-kleinzelliges Lungenkarzinom (NSCLC)
ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients
Successful Treatment of a Resistant Subclone in ALK-Rearranged NSCLC
Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC
Brigatinib : neue Option in der Zweitlinie für Crizotinibvorbehandelte, ALK+ NSCLC Patienten
Successful salvage surgery followed by second ALK–TKI after alectinib failure in a patient with ALK-positive NSCLC
Podcast on Lorlatinib as a First-Line Treatment Option for Patients with ALK-Positive Metastatic NSCLC with Brain Metastasis
Progression patterns, resistant mechanisms and subsequent therapy for ALK-positive NSCLC in the era of second-generation ALK-TKIs
ALK-positives NSCLC: signifikant verbessertes progressionsfreies Überleben unter Brigatinib : Erfahrungsberichte aus dem Alltag
Alecensa bei ALK-positivem NSCLC
Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
Inhibiting ALK-TOPK signaling pathway promotes cell apoptosis of ALK-positive NSCLC
Therapie des ALK+ NSCLC - Brigantinib in der Erstlinie [1, 3] : nicht-kleinzelliges Lungenkarzinom (NSCLC)
ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients
Successful Treatment of a Resistant Subclone in ALK-Rearranged NSCLC
Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC
Brigatinib : neue Option in der Zweitlinie für Crizotinibvorbehandelte, ALK+ NSCLC Patienten
Successful salvage surgery followed by second ALK–TKI after alectinib failure in a patient with ALK-positive NSCLC
Podcast on Lorlatinib as a First-Line Treatment Option for Patients with ALK-Positive Metastatic NSCLC with Brain Metastasis
Progression patterns, resistant mechanisms and subsequent therapy for ALK-positive NSCLC in the era of second-generation ALK-TKIs
ALK-positives NSCLC: signifikant verbessertes progressionsfreies Überleben unter Brigatinib : Erfahrungsberichte aus dem Alltag
Alecensa bei ALK-positivem NSCLC
Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
Inhibiting ALK-TOPK signaling pathway promotes cell apoptosis of ALK-positive NSCLC
Therapie des ALK+ NSCLC - Brigantinib in der Erstlinie [1, 3] : nicht-kleinzelliges Lungenkarzinom (NSCLC)
ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients
Successful Treatment of a Resistant Subclone in ALK-Rearranged NSCLC
Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC
Brigatinib : neue Option in der Zweitlinie für Crizotinibvorbehandelte, ALK+ NSCLC Patienten
Successful salvage surgery followed by second ALK–TKI after alectinib failure in a patient with ALK-positive NSCLC
Podcast on Lorlatinib as a First-Line Treatment Option for Patients with ALK-Positive Metastatic NSCLC with Brain Metastasis
Progression patterns, resistant mechanisms and subsequent therapy for ALK-positive NSCLC in the era of second-generation ALK-TKIs